Key Points Interested in Stoke Therapeutics, Inc.? Here are five stocks we like better. Stoke’s Phase III EMPEROR trial for zorevunersen in Dravet syndrome remains on…
Quince Therapeutics stock plummets after revealing strategic alternatives Read More: Quince Therapeutics stock plummets after revealing strategic alternatives
A competitor recently earned FDA approval, but this drug is reportedly going to be pricey.An analyst’s very bullish new research note was the spark that lit…
OnKure Therapeutics CEO Saccomano sells $230 in stock Read More: OnKure Therapeutics CEO Saccomano sells $230 in stock By Investing.com
Rothblatt (United Therapeutics) sells $3.1m in UTHR stock Read More: Rothblatt (United Therapeutics) sells $3.1m in UTHR stock By Investing.com
BOSTON–Greatland Realty Partners and Barings announced that TreeFrog Therapeutics, a French-based biotech company specializing in cell therapy, will join Cambridgeport Labs, leasing 13,488 square feet. TreeFrog…
23andMe is laying off 40 per cent of its workforce, or more than 200 employees, and discontinuing its therapeutics division as the struggling genetic testing company attempts…
In a recent transaction involving Camp4 Therapeutics Corp (NASDAQ:CAMP), key investors have made significant stock acquisitions. AH Bio Fund I, L.P. and AH Bio Fund IV,…
It’s hard to go wrong with either company, but one is more appealing. Viking Therapeutics (VKTX 5.43%) and Summit Therapeutics (SMMT 7.20%) are both up-and-coming biotechs…
The biotech continued to get attention from both pundits and investors, thanks largely to its investigational obesity drug. Viking Therapeutics (VKTX 11.31%) stormed the stock market…